PARK:NASDAQPark Dental Partners, Inc. Analysis
Data as of 2026-05-20 - not real-time
$18.79
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Technical indicators show a bullish alignment as the short‑term moving average sits above the longer‑term averages, the RSI remains in the upper‑mid range, and the MACD histogram is positive, all supported by an increasing volume trend. The price is trading above the identified support level and below the next resistance, with a fair‑value estimate from discounted cash flow suggesting a material upside.
Fundamental backdrop includes a modest year‑over‑year revenue increase driven by higher patient visits and recent acquisition activity, while operating margins remain negative and the company carries a high debt‑to‑equity ratio. Share‑based compensation expense is expected to decline, which could improve cash flow, and the analyst consensus leans strongly toward a buy recommendation despite the current lack of dividend payouts.
Fundamental backdrop includes a modest year‑over‑year revenue increase driven by higher patient visits and recent acquisition activity, while operating margins remain negative and the company carries a high debt‑to‑equity ratio. Share‑based compensation expense is expected to decline, which could improve cash flow, and the analyst consensus leans strongly toward a buy recommendation despite the current lack of dividend payouts.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical setup with price above short‑term support
- Negative operating margin and earnings per share
- Increasing volume indicating market interest
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF‑derived fair value indicating ~20% upside
- Revenue growth from higher patient volumes and acquisitions
- Improving cash flow as share‑based compensation expense normalizes
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic expansion potential in multiple states
- Stable demand for dental services within a defensive healthcare sector
- Undervalued price relative to industry peers and fair‑value estimate
Key Metrics & Analysis
Financial Health
Revenue Growth2.70%
Profit Margin-0.93%
P/E Ratio11.9
ROE-18.60%
ROA-1.53%
Debt/Equity234.88
P/B Ratio3.7
Op. Cash Flow$16.8M
Free Cash Flow$9.0M
Industry P/E27.2
Technical Analysis
TrendBullish
RSI59.5
Support$16.66
Resistance$19.58
MA 20$17.93
MA 50$17.49
MA 200$16.83
MACDBullish
VolumeIncreasing
Fear & Greed Index89.45
Valuation
Fair Value$21.14
Target Price$22.75
Upside/Downside21.08%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.66
Volatility32.62%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.